TAE Life Sciences, a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced closing of the initial phase of the B-round funds from a consortium of investors. Investors, including ARTIS Ventures who led the company’s initial funding in 2018, raised $30M in this round. The investment will enable TLS to move beyond the current boron-10 drug, BPA, and speed development of novel proprietary boron-10 target drugs while simultaneously honing its neutron beam accelerator technology for BNCT. BNCT is a particle therapy designed to selectively destroy cancer cells without damaging neighboring healthy cells. TLS is the only company to focus on the parallel development of new boron-10 drugs and a neutron accelerator system, a combination aimed at difficult-to-treat cancers.
According to the company, BNCT offers advantages over conventional radiotherapy and even more advanced particle therapy such as the proton and carbon ion. BNCT is a combination treatment that uses the biological targeting precision of boron-10, which acts as a homing beacon and the activation by a neutron source. When the boron-containing cells are irradiated by epithermal neutrons, the combination releases a highly localized therapeutic dose that destroys cancer on a cell-by-cell basis with minimal damage to healthy tissues. BNCT minimizes the need for physical targeting accuracy and complex tumor motion management procedures. Instead, the therapy targets cancer cells biologically by the boron-carrying drugs that preferentially target tumor tissue as well as undetected microscopic cancer cells.
“For patients suffering from complex cancers, BNCT may offer a quicker, effective path to cancer cell destruction, with fewer side effects,” said Bruce Bauer, Chief Executive Officer of TAE Life Sciences. “TLS’s goal is to continue to increase the efficacy of the combination while bringing costs down so that more clinicians, hospitals, and patients can access this treatment.”